These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 20726904)
1. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008. Prosperi MC; Cozzi-Lepri A; Antinori A; Cassola G; Torti C; Ursitti MA; Pellizzer GP; Giacometti A; d'Arminio Monforte A; De Luca A; HIV Med; 2011 Mar; 12(3):174-82. PubMed ID: 20726904 [TBL] [Abstract][Full Text] [Related]
2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254 [TBL] [Abstract][Full Text] [Related]
3. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S; Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932 [TBL] [Abstract][Full Text] [Related]
5. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G; J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879 [TBL] [Abstract][Full Text] [Related]
6. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. Collazos J; Asensi V; Cartón JA AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038 [TBL] [Abstract][Full Text] [Related]
7. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting. Bloch M; Farris M; Tilden D; Gowers A; Cunningham N Sex Health; 2010 Mar; 7(1):17-24. PubMed ID: 20152091 [TBL] [Abstract][Full Text] [Related]
8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
10. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F; HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859 [TBL] [Abstract][Full Text] [Related]
11. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA. Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246 [TBL] [Abstract][Full Text] [Related]
12. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071 [TBL] [Abstract][Full Text] [Related]
13. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion. Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848 [TBL] [Abstract][Full Text] [Related]
14. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062 [TBL] [Abstract][Full Text] [Related]
15. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104 [TBL] [Abstract][Full Text] [Related]
16. Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. Schiffer V; Deveau C; Meyer L; Iraqui I; Nguyen-Wartel A; Chaix ML; Delfraissy JF; Rouzioux C; Venet A; Goujard C; HIV Med; 2004 Sep; 5(5):326-33. PubMed ID: 15369507 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217 [TBL] [Abstract][Full Text] [Related]
18. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544 [TBL] [Abstract][Full Text] [Related]
19. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy. Solmone M; Girardi E; Lalle E; Abbate I; D'Arminio Monforte A; Cozzi-Lepri A; Alessandrini A; Piscopo R; Ebo F; Cosco L; Antonucci G; Ippolito G; Capobianchi MR; ; Antivir Ther; 2006; 11(1):87-94. PubMed ID: 16518964 [TBL] [Abstract][Full Text] [Related]